nafamostat has been researched along with Exanthem in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uwagawa, T | 1 |
| Sakamoto, T | 1 |
| Yasuda, J | 1 |
| Shiozaki, H | 1 |
| Furukawa, K | 1 |
| Onda, S | 1 |
| Gocho, T | 1 |
| Shiba, H | 1 |
| Yanaga, K | 1 |
1 trial available for nafamostat and Exanthem
| Article | Year |
|---|---|
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Chemotherapy, Adjuvant; Combined | 2021 |